KPV Peptide: What the Research Record Shows

The short version

KPV is a three-amino-acid peptide, lysine-proline-valine, that forms the C-terminal tail of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied because that short fragment appears to keep much of alpha-MSH’s anti-inflammatory activity while shedding the receptor-binding sequence that drives pigmentation. That is the whole basis of the interest in it, and it is a legitimate research question with roughly two decades of laboratory work behind it.

What the research record does not contain is a human trial. A search of ClinicalTrials.gov on 29 August 2026, using KPV both as an intervention name and as a general search term, returned zero registered studies.^[10] So the honest summary is: an interesting mechanism, consistent rodent and cell-culture signals, several plausible clinical targets, and no clinical evidence in people at all.

What KPV actually is

Alpha-MSH is a 13-residue hormone. KPV is residues 11 through 13, which is why the older literature writes it as alpha-MSH(11-13). The pharmacologically important point is that the melanocortin receptor pharmacophore sits elsewhere in the molecule. A 2010 review by Brzoska and colleagues describes KPV as lacking the entire sequence motif required to bind any known melanocortin receptor, while retaining almost all of the anti-inflammatory capacity of the parent hormone.^[9]

If that holds, KPV would be acting through something other than the classic melanocortin receptors. Two candidate mechanisms show up repeatedly in the literature: uptake by the di/tripeptide transporter PepT1, and direct interference with NF-kB signaling inside the cell. Both are supported by cell work, neither has been confirmed in humans. For background on how fragments like this are named, isolated, and studied, see our notes on what counts as a research peptide.

The inflammatory bowel disease work

The most substantial body of KPV research comes from Didier Merlin’s group and centers on the gut.

The anchor paper is Dalmasso and colleagues in Gastroenterology in 2008.^[1]PepT1 is a di/tripeptide transporter normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. The authors asked whether KPV’s anti-inflammatory effect depends on that transporter. They worked in Caco2-BBE and HT29-Cl.19A intestinal epithelial lines and in Jurkat T cells, and in two mouse colitis models, DSS and TNBS. The reported conclusion is that KPV is taken up through PepT1 at low (nanomolar-range) concentrations in cells expressing the transporter, that it suppresses NF-kB and MAP kinase signaling, and that oral administration reduced colitis severity in mice.

A separate group reached a compatible conclusion the same year.^[2] Kannengiesser and colleagues tested KPV in DSS colitis and in CD45RB-high transfer colitis. Treated animals recovered earlier, regained significantly more body weight, and showed reduced inflammatory infiltrate and lower myeloperoxidase activity. The most interesting detail is that they ran the experiment in MC1Re/e mice, which carry a nonfunctional melanocortin-1 receptor, and KPV still worked, rescuing all animals in the treatment group from death during DSS colitis. That is direct experimental support for the claim that KPV acts independently of MC1R.

Viennois and colleagues extended the PepT1 story to colitis-associated cancer in 2016.^[4] PepT1 overexpression increased tumor burden in mice and deletion decreased it. KPV prevented carcinogenesis in wild-type animals but had no protective effect when PepT1 was absent, which is a clean mechanistic control.

This is a coherent, internally consistent rodent literature. It is also, still, a rodent literature.

Wound healing, eye, and mucosa

Outside the gut, the strongest single result is ophthalmic. Bonfiglio and colleagues abraded the entire corneal epithelium in rabbits and applied topical KPV at 1, 5, or 10 mg/mL, two drops four times daily for four days.^[5] By 60 hours, 8 of 8 KPV-treated corneas were completely re-epithelialized while none of the vehicle-treated controls were. Pretreatment with the nitric oxide synthase inhibitor L-NAME abolished the effect, implicating nitric oxide in the mechanism.

Shao and colleagues loaded KPV into a temperature-sensitive hydrogel and applied it to chemotherapy-induced oral mucositis in rats.^[8] Treated animals ate more and regained weight, IL-1beta and TNF-alpha fell, IL-10 rose, and the ulcerated gingiva showed better tissue repair. One caveat matters here and is usually dropped when this study is cited: the hydrogel also contained epigallocatechin-3-gallate, which the authors selected specifically for its inherent antibacterial activity. The antibacterial effect against S. aureus and MRSA in that study belongs to the composite formulation, not demonstrably to KPV alone.

The antimicrobial claim is weaker than it sounds

KPV is frequently marketed as an antimicrobial peptide. The primary literature is not settled on this, and at least one careful attempt to reproduce it failed.

Songok and colleagues, in PLoS One in 2018, tested Ac-KPV-NH2 and glycoalkylated analogs in antimicrobial assays under a variety of conditions and reported no activity for any of them.^[7] Their glycoalkylation did improve resistance to proteolytic enzymes, which was the point of the paper, but the antimicrobial result was negative. Reviews that describe alpha-MSH C-terminal fragments as antimicrobial are generally summarizing work on alpha-MSH itself or on longer fragments. If you see KPV sold as an antibacterial or antifungal agent, that specific claim is not well supported by the peptide-alone data.

Delivery is the actual unsolved problem

This is where most consumer KPV products run into trouble, and it is the part of the record worth reading closely.

Pawar and colleagues measured KPV permeation across dermatomed human skin.^[6] By simple passive diffusion, KPV permeation was below the detection limit of the assay (0.01 micrograms/mL). Microneedle microporation raised it to 4.4 micrograms/cm²/h. Adding iontophoresis, or iontophoresis plus microneedles, increased the rate by 8-fold and 35-fold respectively over microneedles alone. In plain terms: KPV does not meaningfully cross intact human skin on its own. A cream or serum with no microporation or electrical assist is not delivering measurable KPV through the stratum corneum.

The oral picture is similar. The Merlin group’s own follow-up work built hyaluronic-acid-functionalized nanoparticles roughly 272 nm across, then encapsulated them in a chitosan/alginate hydrogel, precisely because free oral KPV does not reliably reach inflamed colonic tissue.^[3]When this much of a field’s output is formulation engineering, that is the field telling you the raw peptide has a delivery problem. Our guides on peptide bioavailability and routes of administration cover why short peptides behave this way in general.

What is missing

No registered human trial. No FDA-approved KPV product and therefore no prescribing information, no approved indication, and no labeled dosing. No published human pharmacokinetics that we could locate: half-life, clearance, and systemic exposure in people are simply unknown. Any human dosing figure circulating online is extrapolated from rodent studies or from vendor marketing, not from a trial, and dosing decisions for any investigational compound are a prescriber’s call, not something a research summary can supply.

This puts KPV in a familiar category alongside other heavily marketed, thinly trialed peptides. Compare the evidence structure with BPC-157, which has a similar shape, or with GHK-Cu, where the topical work is further along.